« Back
Home /
Anti-Human PID/MTA2 - 0.1 mg

Anti-Human PID/MTA2 - 0.1 mg

Item no.	LEIN-P150-0.1mg
Manufacturer	Leinco Technologies
Amount	0.1 mg
Quantity options	0.1 mg 0.5 mg 1 mg 20 ug
Category	Neuroscience Targets for Rodent Neurosciences Antibodies Western Blot Primary Antibodies
Type	Antibody Primary
Applications	WB
Specific against	Human (Homo sapiens)
Host	Rabbit
Citations	1. Matsuoka, S. et al. (1998) Science. 282:1893-7. 2. Tanaka, H. et al. (2000) Nature. 404:42-9. 3. Oda, E. et al. (2000) Science. 288(5468):1053-8. 4. Oda, K. et al. (2000) Cell. 102(6):849-62.
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Category	Primary Monoclonal Antibodies>Apoptosis & Cell Biology
Manufacturer - Targets	PID/MTA2
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description	The p53 tumor-suppressor gene integrates numerous signals that control cell life and death. Several novel molecules involved in p53 pathway, including Chk2 , p53R2 (2), p53AIP1 (3), Noxa (4), PIDD (5), and PID/MTA2 (6), were recently discovered. The transcriptional activity of p53 is modulated by protein stability and acetylation. PID/MTA2, also termed MTA1-L1, was found to be a subunit of nucleosome remodeling and deacetylating (NRD/NuRD) complex (6-8). PID/MTA2 modulates the enzymatic activity of the histone deacetylase complex and its expression reduces the levels of acetylated p53. Deacetylation of p53 by PID/MTA2 represses p53-dependent transcriptional activation and modulates p53-mediated cell growth arrest and apoptosis (6). PID/MTA2 is ubiquitously expressed in human tissues (8).
Background	The p53 tumor-suppressor gene integrates numerous signals that control cell life and death. Several novel molecules involved in p53 pathway, including Chk2 , p53R2 (2), p53AIP1 (3), Noxa (4), PIDD (5), and PID/MTA2 (6), were recently discovered. The transcriptional activity of p53 is modulated by protein stability and acetylation. PID/MTA2, also termed MTA1-L1, was found to be a subunit of nucleosome remodeling and deacetylating (NRD/NuRD) complex (6-8). PID/MTA2 modulates the enzymatic activity of the histone deacetylase complex and its expression reduces the levels of acetylated p53. Deacetylation of p53 by PID/MTA2 represses p53-dependent transcriptional activation and modulates p53-mediated cell growth arrest and apoptosis (6). PID/MTA2 is ubiquitously expressed in human tissues (8).
PubMed	PID/MTA2
Manufacturer - Specificity	Rabbit Anti-Human PID/MTA2 recognizes human, mouse and rat PID/MTA2. This polyclonal antibody was purified using affinity chromatography.
RRID	AB_2831527
Concentration	0.5 mg/ml
Formulation	This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen	PN:P152
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-P150-0.1mg-safety-datasheet.pdf